IT202000001567A1 - Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi. - Google Patents

Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.

Info

Publication number
IT202000001567A1
IT202000001567A1 IT102020000001567A IT202000001567A IT202000001567A1 IT 202000001567 A1 IT202000001567 A1 IT 202000001567A1 IT 102020000001567 A IT102020000001567 A IT 102020000001567A IT 202000001567 A IT202000001567 A IT 202000001567A IT 202000001567 A1 IT202000001567 A1 IT 202000001567A1
Authority
IT
Italy
Prior art keywords
pharmaceutically acceptable
salts
lymphids
myeloids
pik3c3
Prior art date
Application number
IT102020000001567A
Other languages
English (en)
Inventor
Vincenzo Ciminale
Vittoria Raimondi
Francesco Ciccarese
Original Assignee
Univ Degli Studi Padova
St Oncologico Veneto Iov Irccs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Padova, St Oncologico Veneto Iov Irccs filed Critical Univ Degli Studi Padova
Priority to IT102020000001567A priority Critical patent/IT202000001567A1/it
Priority to PCT/IB2021/050610 priority patent/WO2021152467A1/en
Publication of IT202000001567A1 publication Critical patent/IT202000001567A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT102020000001567A 2020-01-28 2020-01-28 Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi. IT202000001567A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102020000001567A IT202000001567A1 (it) 2020-01-28 2020-01-28 Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.
PCT/IB2021/050610 WO2021152467A1 (en) 2020-01-28 2021-01-27 Combinations comprising bh3-mimetic compounds and inhibitors of early stages of autophagy for use in the treatment of non-hodgkin's b-cell lymphomas and lymphoid and/or myeloid leukemias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102020000001567A IT202000001567A1 (it) 2020-01-28 2020-01-28 Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.

Publications (1)

Publication Number Publication Date
IT202000001567A1 true IT202000001567A1 (it) 2021-07-28

Family

ID=71575505

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102020000001567A IT202000001567A1 (it) 2020-01-28 2020-01-28 Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.

Country Status (2)

Country Link
IT (1) IT202000001567A1 (it)
WO (1) WO2021152467A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114949230A (zh) * 2022-06-13 2022-08-30 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085815A1 (en) * 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
WO2019070777A2 (en) * 2017-10-04 2019-04-11 University Of Maryland, Baltimore County PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS FOR THE TREATMENT OF CANCERS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085815A1 (en) * 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
WO2019070777A2 (en) * 2017-10-04 2019-04-11 University Of Maryland, Baltimore County PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS FOR THE TREATMENT OF CANCERS

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Handbooko 'pl7armaceutical excipients", 2009
"pharmaceutical tablets for dosage forms", 1989, MARCEL DEKKER, INC.
"Remington - the Science and practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
ANDERSON, M. A. ET AL.: "The BCL2 selective inhibitor venetoclax induced rapid onset apoptosis of CLL cells in patients via to TP53-independant mechanism", BLOOD, vol. 127, 2016, pages 3215 - 3224
ANSEL ET AL.: "pharmaceutical dosage forms and drug delivery systems", 1995, WILLIAMS AND WILKINS
AW ROBERTS ET AL: "Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies : Basic science and clinical application of venetoclax", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 101, no. 1, 26 November 2016 (2016-11-26), US, pages 89 - 98, XP055723699, ISSN: 0009-9236, DOI: 10.1002/cpt.553 *
CHIARETTI, S.FOA, R.: "Acute lymphoblastic leukemia T-cell", HAEMATOLOGY, vol. 94, no. 2, 2009, pages 160 - 162, XP055435422, DOI: 10.3324/haematol.2008.004150
CHOU, T. C.: "Drug combination studies and their synergy quantification using the Chou-Talalay method", CANCER RES, vol. 70, 2010, pages 440 - 446, XP055169871, DOI: 10.1158/0008-5472.CAN-09-1947
DALBY, K. NO.TEKEDERELI, I.LOPEZ-BERESTEIN, G.OZPOLAT, B.: "Targeting the prolonged and procurvival functions of autophagy as novel therapeutic strategies in cancer", AUTOPHAGY, vol. 6, 2010, pages 322 - 329
DE KOUCHKOVSKY, I.ABDUL-HAY, M.: "Acute myeloid leukemia: A comprehensive review and 2016 update", BLOOD CANCER J, vol. 6, no. 7, 2016, pages e441, XP002793132, DOI: 10.1038/bcj.2016.50
FERNALD, K.KUROKAWA, M.: "Fading apoptosis in cancer", TRENDS CELL, vol. 23, 2013, pages 620 - 633
HANAHAN, D.WEINBERG, R. A.: "The next generation", CELI, vol. 144, 2011, pages 646 - 674, XP028185429, DOI: 10.1016/j.cell.2011.02.013
KONOPLEVA, M. ET AL.: "Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia", CANCER DISCOV, vol. 10, 2016, pages 1106 - 1117, XP055642391, DOI: 10.1158/2159-8290.CD-16-0313
LEVERSON, J.D.COJOCARI, D.: "Hematologic tumor Cell resistance to the BCL-2 inhibitor Venetoclax: A Product of its Microenvironment?", FRONT. ONCOL., vol. 8, 2018, pages 458
MARINA KONOPLEVA ET AL: "Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia", CANCER DISCOVERY, vol. 6, no. 10, 12 August 2016 (2016-08-12), US, pages 1106 - 1117, XP055642391, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-16-0313 *
MOHAMED RAHMANI ET AL: "Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process", BLOOD, vol. 119, no. 25, 21 June 2012 (2012-06-21), US, pages 6089 - 6098, XP055735345, ISSN: 0006-4971, DOI: 10.1182/blood-2011-09-378141 *
P. STAHLC. WERMUTH: "Handbook of pharmaceutical sales", 2008, WILEY-VCH, pages: 127 - 133
PEI, G. ET AL.: "Autophagy Facilities Metadherin-induced chemotherapy resistance through the AMPP/ ATG5 pathway in gastric Cancer", CELL PHYSIOL BIOCHEM, vol. 46, 2018, pages 847 - 859
PEIRS, S. ET AL.: "ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in acute lymphoblastic leukemia T-cell", BLOOD, vol. 25, 2014, pages 3738 - 3747
ROBERTS, A. W.HUANG, D.: "Targeting BCL2 with BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and related B Celi Malignancies", CLIN PHARMACOL THER, vol. 101, 2017, pages 89 - 98
RUBINSTEIN, A. D.KIMCHI, A.: "Life in the balance - a mechanistic view of the crosstalk between autophagy and apoptosis", J CELISEI, vol. 125, 2012, pages 5259 - 5268
SMITH LINDSAY D ET AL: "BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 34, no. 2, 28 August 2019 (2019-08-28), pages 640 - 644, XP037003027, ISSN: 0887-6924, [retrieved on 20190828], DOI: 10.1038/S41375-019-0557-Y *
SOUERS, A. J. ET AL.: "ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while shooting platelets", NA T. MED., vol. 19, 2013, pages 202 - 208

Also Published As

Publication number Publication date
WO2021152467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
IT201900023895A1 (it) Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
CY1119767T1 (el) Παραγωγα πιπεριδινυλικης ινδολης και η χρηση τους ως αναστολεις του παραγοντα β του συμπληρωματος
PH12020550238A1 (en) Methods for the administration of certain vmat2 inhibitors
BR112018002585A2 (pt) 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amina para uso no tratamento de câncer
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2019002555A2 (es) Composición farmacéutica
BR112017017135A2 (pt) inibidores de tgf-beta
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
CY1115681T1 (el) Θεραπευτικες ενωσεις
DOP2019000184A (es) Inhibidores selectivos de jak1
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
MA31218B1 (fr) Forme galenique secable permettant une liberation modifiee du principe actif
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
ECSP088680A (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
IT202000001567A1 (it) Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi.
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina
CL2022000725A1 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
NO20054607L (no) Nitrogenholdig heterosyklisk derivat som har 2,6-disubstituert styryl
DE602006006546D1 (de) 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung
CO2022017622A2 (es) Inhibidores de quinasa nek7
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CO2022019131A2 (es) Inhibidores de la quinasa nek7